HC Wainwright reiterated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $15.00 price target on the stock.
Lisata Therapeutics Trading Up 5.3 %
Shares of Lisata Therapeutics stock opened at $3.18 on Wednesday. The stock has a market capitalization of $26.42 million, a price-to-earnings ratio of -1.29 and a beta of 1.21. Lisata Therapeutics has a twelve month low of $1.99 and a twelve month high of $3.83. The business’s 50 day simple moving average is $3.11 and its 200-day simple moving average is $3.11.
Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.14. During the same period last year, the business earned ($0.50) earnings per share. Sell-side analysts predict that Lisata Therapeutics will post -2.97 earnings per share for the current year.
Institutional Trading of Lisata Therapeutics
About Lisata Therapeutics
Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.
See Also
- Five stocks we like better than Lisata Therapeutics
- Most active stocks: Dollar volume vs share volume
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Ride Out The Recession With These Dividend KingsĀ
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- How to Use the MarketBeat Excel Dividend Calculator
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.